Christos S Karapetis

Summary

Affiliation: Flinders University
Country: Australia

Publications

  1. ncbi Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up
    C S Karapetis
    Department of Medical Oncology, Guy s Hospital, London, United Kingdom
    Intern Med J 33:427-35. 2003
  2. ncbi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
  3. ncbi A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas
    Christos S Karapetis
    Department of Medical Oncology, Guy s Hospital, London, UK
    Asia Pac J Clin Oncol 6:298-305. 2010
  4. ncbi PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis
    C S Karapetis
    Department of Medical Oncology, Guy's Hospital, London, UK
    Ann Oncol 12:1485-8. 2001
  5. ncbi Cetuximab for the treatment of colorectal cancer
    Derek J Jonker
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
    N Engl J Med 357:2040-8. 2007

Detail Information

Publications5

  1. ncbi Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up
    C S Karapetis
    Department of Medical Oncology, Guy s Hospital, London, United Kingdom
    Intern Med J 33:427-35. 2003
    ..The objective of the present study was to evaluate the use of FDG-PET in the setting of advanced GCT, and to determine the influence of FDG-PET on subsequent patient management...
  2. ncbi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  3. ncbi A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas
    Christos S Karapetis
    Department of Medical Oncology, Guy s Hospital, London, UK
    Asia Pac J Clin Oncol 6:298-305. 2010
    ..Epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) is a well-established chemotherapy regimen but a continuous chemotherapy infusion is not always feasible or acceptable...
  4. ncbi PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis
    C S Karapetis
    Department of Medical Oncology, Guy's Hospital, London, UK
    Ann Oncol 12:1485-8. 2001
    ..Sarcoidosis, a condition that has been associated with testicular cancer, should always be considered in the differential diagnosis...
  5. ncbi Cetuximab for the treatment of colorectal cancer
    Derek J Jonker
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
    N Engl J Med 357:2040-8. 2007
    ..Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR...